Navigation Links
Five-Year Data Demonstrate Long-Term Efficacy and Safety with ORENCIA(R) (abatacept) in Adults with Rheumatoid Arthritis Who had an Inadequate Response to Methotrexate
Date:11/9/2007

- Data Presented at American College of Rheumatology Annual Meeting -

BOSTON, Nov. 9 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE: BMY) today announced that cumulative five-year data from an open-label long-term extension of a Phase IIb trial demonstrate the long-term efficacy and safety of ORENCIA(R) (abatacept) in adult rheumatoid arthritis (RA) patients who had an inadequate response to methotrexate (MTX). The data show that, in these patients, ORENCIA provided sustained improvements in ACR responses, physical function and health-related quality of life. These data, combined with the retention rates observed in this study, demonstrate that ORENCIA provides durable long-term clinical benefits in patients with active RA who had an inadequate response to MTX. Results of this study were presented at the 2007 American College of Rheumatology (ACR) Annual Scientific Meeting.

"Studying the long-term efficacy of a treatment is important because RA is a chronic disease," said Joel Kremer, M.D., Chief of Rheumatology, Albany Medical College. "These data are important because they show that ORENCIA is efficacious and has an acceptable safety profile over an extended period of time in patients with an inadequate response to methotrexate."

Details of the Study

Patients in the initial one-year, double-blind, placebo-controlled randomized trial received MTX and either ORENCIA (10 mg/kg or 2 mg/kg) or placebo administered as a 30-minute intravenous infusion on Days 1, 15 and 30, and every four weeks thereafter, in addition to MTX. The primary endpoint of the double-blind portion of the study was ACR 20 at 6 months (60 percent for ORENCIA(R) (abatacept) vs. 35.5 percent for placebo). All patie
'/>"/>

SOURCE Bristol-Myers Squibb Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
2. Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent
3. Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting
4. Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial
5. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
6. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
7. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
8. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
9. Nebivolol Lowers Blood Pressure in Mild-to-Moderate Hypertensive Patients as Demonstrated in a Study Published in the Journal of Clinical Hypertension
10. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
11. R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... HYDERABAD, India , July 31, 2015 /PRNewswire/ ... Billing and CRM solutions for video, data and cloud ... (PoC) with a leading pharma giant for Internet ... managing different IoT applications offered on subscription model. ... Pharma giant is striving for business ...
(Date:7/30/2015)... COLUMBUS, Ohio, July 30, 2015 Mettler-Toledo International ... results for 2015.  Provided below are the highlights: ... the quarter compared with the prior year. Reported sales ... in the quarter. , Net earnings per diluted ... in the prior-year period. Adjusted EPS was $2.80 , ...
(Date:7/30/2015)... MOUNTAIN VIEW, Calif. , July 30, 2015 /PRNewswire/ ... that it will release its second quarter 2015 financial ... 6, 2015.   In conjunction with the release, the ... community at 5:00 p.m. Eastern Time on ... results of the quarter and other business developments. ...
Breaking Medicine Technology:Magnaquest Signs a POC With a Leading Pharma Giant in Europe to Manage Subscription Management and Billing for Internet of Things (IoT) 2Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 14IRIDEX Announces Second Quarter 2015 Conference Call and Release Date 2
... 23, 2011 Solos Endoscopy, Inc. (OTCPK: SNDY) is ... and interactive website, www.solosendoscopy.com on Friday July ... catalog" for existing and new customers and includes comprehensive ... updated look showcases streamlined navigation to allow for easy-to-use ...
... GAITHERSBURG, Md., June 23, 2011 Sirnaomics, Inc. ... has signed a partnership agreement with Guangdong Zhongsheng ... on the Shenzhen Stock Exchange (SZSE: 002317). The ... RNA (siRNA) therapeutics to treat diabetic retinopathy and ...
Cached Medicine Technology:Solos Endoscopy, Inc. To Launch New Corporate Website 2Sirnaomics Seals a Second Partnership Deal with a Chinese Pharmaceutical Company for Developing siRNA Therapeutics 2Sirnaomics Seals a Second Partnership Deal with a Chinese Pharmaceutical Company for Developing siRNA Therapeutics 3
(Date:7/31/2015)... Atlanta, GA (PRWEB) , ... July 31, 2015 , ... ... CoolSculpting , the CoolSmooth PRO this week. Zeltiq Aesthetics released this new applicator ... FDA in January 2014 for treating the outer thighs. The original applicator required ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... at its new True North Conference Center. The medical community, social workers, law ... community may be more aligned in the effort to better understand and combat ...
(Date:7/31/2015)... ... , ... Coco Libre announced today that their flagship Organic Coconut Water will ... US Open of Surfing, July 25 through August 2 in Huntington Beach, California. Coco ... market, is a natural choice given the Open’s commitment to sustainable practices. , ...
(Date:7/31/2015)... ... July 31, 2015 , ... Ticket Down is a reliable ... looking to catch a new and refreshing show on Broadway, look no further than ... including an Obie Award, Outer Critics Circle Award, Drama Desk Award, Lucille Lortel Award, ...
(Date:7/31/2015)... CA (PRWEB) , ... July 31, 2015 , ... According ... and cosmetic experts gathered to see if they could reach a consensus on the ... breast augmentation and facelifts. Overall, the group reached 90 percent consensus on a series ...
Breaking Medicine News(10 mins):Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 3Health News:Coco Libre Brings Eco-conscious Hydration to Vans US Open of Surfing 2Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 2Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 3Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 4Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 5Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 6Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 7Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 3
... hip is a growing problem that will continue to ... on risk factors for developing OA, but few have ... new study published in the December issue of Arthritis ... hip pain to determine their disease progression and to ...
... with the United States, Food and Drug Administration (FDA) ... the treatment of metastatic adenocarcinoma of the ... upper gastrointestinal tract, MONTREAL, ... will compare SP1049C plus Best Supportive Care (BSC),versus BSC alone for ...
... YORK (Nov. 29, 2007) -- There ... individuals in the U.S. diagnosed with chronic Immune ... reduces the number of platelets in their blood ... hemorrhages. Now, the results of an international multicenter ...
... today that life,sDHA(TM), its patented, vegetarian form of ... heart health, is now,available in three new products ... schnitzel, and cordon bleu, and will all,contain 40 ... Based in The,Netherlands, Dalco Foods provides food products ...
... , , WEDNESDAY, Nov. 28 (HealthDay News) -- The number of ... since the 1980s, and that means an increased risk of ... of radiation, a new report contends. , Today, more than ... United States, compared with 3 million in 1980. A CT ...
... African-American men face an observable disadvantage versus Caucasian ... Not only is prostate cancer detected later in African ... treat. , Findings on the social and ... today at the American Association for Cancer Research conference ...
Cached Medicine News:Health News:Identifying patients at high risk for total hip replacement 2Health News:Supratek Pharma Inc. announced today that under the Special Protocol 2Health News:Eltrombopag studied in Idiopathic Thrombocytopenic Purpura 2Health News:Martek's life'sDHA(TM) Featured in Dalco Foods Wellness Line Meat Products 2Health News:Martek's life'sDHA(TM) Featured in Dalco Foods Wellness Line Meat Products 3Health News:Rise in CT Scans Poses Cancer Risk 2Health News:Rise in CT Scans Poses Cancer Risk 3Health News:Genetic and behavioral differences add to prostate cancer disparities 2Health News:Genetic and behavioral differences add to prostate cancer disparities 3Health News:Genetic and behavioral differences add to prostate cancer disparities 4Health News:Genetic and behavioral differences add to prostate cancer disparities 5
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: